Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Bristol-Myers Squibb CoTrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs Recursion Pharmaceuticals Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.66 (market cap $129.94B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.81B). The key difference: Bristol-Myers Squibb Co is far larger — about 71.8× Recursion Pharmaceuticals Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

BMYRXRX
Market Cap
$129.94B$1.81B
Sector
HealthHealth
52-Week High
$65.89$6.79
52-Week Low
$42.60$2.84
Enterprise Value
$163.92B$1.33B
Dividend Yield
3.96%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX